2nd Quarter - Report

FRESENIUS MEDICAL CARE NORTH AMERICA for FRESENIUS MEDICAL CARE NORTH AMERICA

Firm
Client
Income
—
Expenses
$1,570,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

S. 4574/H.R. 8254 (from 116th Congress) Bringing Enhanced Treatments and Therapies to ESRD Recipients Kidney Care Act (not yet introduced in the 117th Congress) Federal allocation of COVID-19 vaccine for dialysis centers Legislation related to telehealth and dialysis centers Administrations CMMI Model for Kidney Disease- Delay of voluntary models and ESRD Treatment Telehealth policies/CMS Waivers H.R.1332 - Telehealth Modernization Act Charitable Premium Assistance Transitional Drug Add-on Payment Adjustment (TDAPA) H.R. 4065- Chronic Kidney Disease Improvement in Research and Treatment Act Value-based care options for ESRD beneficiaries H.R.7609 - Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2021

Foreign entity interest: Fresenius Medical Care AG and Co. KGaA is the sole indirect owner of Fresenius Medical Care Holdings, Inc. (dba Fresenius Medical Care North America) and has an interest in the issues lobbied.

LobbyistCovered position, as disclosed
CHRISTOPHER F BUKI —
STACEY FAHRNER —
LAURA KEMPER —
CAMERON LYNCH —
TALEEN MEKHDJAVAKIAN —

Contacted: SENATE; Office of the Vice President of the United States; Executive Office of the President (EOP); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES

Bills named: S. 4574 (117th), H.R. 4065 (117th), H.R. 8254 (117th), H.R. 7609 (117th), H.R. 1332 (117th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.